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• APRIL is a compact, self-protein that binds two MM antigens (BCMA and TACI) with high 2 9
affinity. We present an APRIL based CAR. 3 0 3 1
• Dual antigen targeting increases the availability of tumour binding sites and reduces the 3 2 risk of antigen negative disease escape. 3 3 Abstract 1 2 B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma 3 (MM), but expression is variable, and early reports of BCMA targeting chimeric antigen 4 receptors (CARs) suggest antigen down-regulation at relapse. Dual antigen targeting 5 increases targetable tumour antigens and reduces the risk of antigen negative disease 6 escape. 'A proliferation-inducing ligand' (APRIL) is a natural high affinity ligand for BCMA 7
and transmembrane activator and CAML interactor (TACI). We quantified surface tumour 8 expression of BCMA and TACI on primary MM cells (n=50). All cases tested expressed 9
BCMA and 39(78%) of them also expressed TACI. We engineered a third generation APRIL-1 0
based CAR (ACAR), which killed targets expressing either BCMA or TACI (p<0.01 and 1 1 p<0.05 respectively, cf control, E:T ratio 16:1). We confirmed cytolysis at antigen levels 1 2 similar to those on primary MM, at low effector to target ratios (56.2±3.9% killing of MM.1s at 1 3 48 hours, E:T ratio 1:32, p<0.01) and of primary MM cells (72.9±12.2% killing at 3 days, E:T 1 4 ratio 1:1, p<0.05, n=5). Demonstrating tumour control in the absence of BCMA, cytolysis of 1 5
primary tumour expressing both BCMA and TACI was maintained in the presence of a 1 6
BCMA targeting antibody. Further, using an intramedullary myeloma model, ACAR T-cells 1 7
caused regression of established tumour within 2 days. Finally, in an in vivo model of 1 8 tumour escape, there was complete ACAR-mediated tumour clearance of BCMA+TACI-and 1 9
BCMA-TACI+ cells while a scFv CAR targeting BCMA alone resulted in outgrowth of BCMA 2 0 negative tumour. These results support the clinical potential of this approach. 2 1
Introduction 1
Multiple myeloma (MM) is a cancer of plasma cells (PC) which is responsible for 2% of 2 cancer deaths 1 . Myeloma remains largely incurable, despite significant progress seen with 3 the inclusion of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) into the 4 mainstay of treatment regimens 2 . Furthermore, current therapeutic strategies fail to benefit 5 approximately 15% of patients who have primary refractory disease, and/or adverse 6 genetics 3 . There remains a need for new myeloma therapies with different mechanisms of 7 action, particularly those that can induce durable remissions. 8
Chimeric antigen receptors (CAR) typically graft the specificity of a monoclonal antibody 9
(mAb) onto a T-cell, redirecting T-cell cytotoxicity to tumour by a mechanism unimpeded by 1 0
MHC class restriction 4 . CAR T-cells may have advantages over mAb based approaches 1 1 since CAR T-cells can actively migrate to sites of disease and persist thus engendering a 1 2 sustained rejection of target cells. CD19 directed CAR T-cell therapy has been effective 1 3
against refractory B-cell malignancies and sustained responses are seen in the face of 1 4
chemotherapy resistant disease 5-9 . Applying CAR T-cell therapy to MM however faces 1 5
several challenges not least target antigen selection. CD19 is only expressed in a small 1 6
proportion of tumour cells 10 and well characterized antigens expressed by myeloma such as 1 7
CD38 11, 12 , CD56 13, 14 and CD138 15 may not be suitable targets due to expression outside the 1 8 lymphoid compartment. 1 9 B-cell maturation antigen (BCMA) is a member of the tumor necrosis factor (TNF) receptor 2 0 superfamily, is upregulated at the terminal stages of B-cell maturation, and selectively 2 1 expressed on PC 16, 17 . BCMA is absent on haemopoietic stem cells [16] [17] [18] and is expressed by 2 2 nearly all cases of MM, albeit at variable, and often low density 16 . Consequently, BCMA has 2 3 been targeted by several immunotherapeutic strategies in MM including CAR approaches 2 4
and bispecific T-cell engager (BiTE) therapies 17, [19] [20] [21] [22] [23] . In the first reported clinical trial 2 5
investigating a BCMA targeting CAR, rapid and dose dependent disease response was seen 2 6
in 4 of 12 patients despite substantial tumour load and heavy pre-treatment 24 . However, 2 7
relatively high T-cell doses were needed to achieve durable remissions and, possibly akin to 2 8
CD19 down-regulation in CD19 CAR T-cell studies 25 , loss of BCMA expression at relapse 2 9
was reported 24 . 3 0
Thus, while BCMA is a promising target, challenges of low target density and target escape 3 1 may compromise clinical efficacy. To address this, we hypothesized that dual antigen 3 2 binding would increase the level of targetable antigen on tumour cells, while potentially 3 3
reducing the incidence of antigen negative escape, in this way enhancing therapeutic 3 4 potential and capacity for long term disease control. Transmembrane activator and CAML 3 5
For personal use only. on January 9, 2018. by guest www.bloodjournal.org From interactor (TACI) is also a TNF receptor and is involved in maturation of B-cells, including 1 their maturation to PC 26, 27 . Importantly, TACI is also expressed on MM cells 18, 28, 29 . A 2 proliferation-inducing ligand (APRIL) is a natural ligand of both BCMA and TACI and is an 3 attractive antigen binder as it is a compact, oligomerizing, single domain, self-protein, that 4 binds both MM antigens with high, nanomolar affinity 30, 31 . 5
In this work, we describe a novel CAR construct using a truncated form of (APRIL) as the 6 tumour targeting domain (ACAR), which recognizes both BCMA and TACI on MM cells. We 7 establish ACAR potency at antigen levels seen in clinical samples, at low effector to target 8 ratios (E:T), against primary cells, as well as in murine models of myeloma and tumour 9 escape. 1 0 1 1 Method 1 2
BCMA/TACI quantification 1 3
Mononuclear cells (MNCs) were stained with CD138 APC (MI15) to identify tumour and 1 4 either murine IgG2a PE Isotype control, rat IgG2a PE Isotype control, anti-BCMA PE (clone 1 5
19F2) or anti-TACI PE (clone 1A1). All antibodies from BioLegend. BD Fortessa was used 1 6
for cell acquisition and data analysed using FlowJo_V10 (Treestar). Antibodies bound per 1 7 cell (ABC) was calculated using BD QuantiBRITE TM beads and subtracting ABC of isotype 1 8 control (greater than 100 ABC considered positive). 1 9 2 0
Cloning 2 1
All plasmids were cloned in-house 32 into the oncoretroviral vector SFG 33 and RD114-2 2 pseudotyped supernatant was produced as previously described 32 . Sequence coding for 2 3 residues 116 to 250 of the canonical sequence for APRIL (Uniprot 075888) was cloned 2 4 between signal peptide from IgG kappa chain V-III to CAR scaffolds comprising of either 2 5
IgG1 hinge spacer, CD8 alpha spacer or IgG1 Fc domain 34 co-expressed with RQR8 using 2 6
an in-frame foot-and-mouth-like 2A peptide, TaV 35 . Epidermal growth factor receptor vIII 2 7
(EGFRvIII) and BCMA targeting CARs were engineered using MR1-1 36 or 11-D-5-3 17 scFvs, 2 8
respectively, a CD8 spacer and a CD28-OX40-CD3ζ endodomain. 2 9 3 0
CAR T-cells 3 1
Peripheral blood mononuclear cells (PBMC) obtained by density gradient centrifugation 3 2 (Ficoll Paque, GE lifesciences) were stimulated with CD3 and CD28 antibodies (0.5µg/ml, 3 3
Miltenyl) and IL-2 (100IU/ml, Genescript) then transduced as before 37 to obtain CAR T-cells. 3 4
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Further methods are available in Supplementary Data. 4 5 Results 6
Primary myeloma cells express BCMA and TACI 7
We have previously reported variable surface expression of BCMA on tumour 16 . Here, we 8 sought to quantify expression levels of both BCMA and TACI on the cell surface of primary 9
BM-derived MM cells. 1 0 Ficolled BM MNCs from 50 patients were stained for CD138 to identify tumour and anti-1 1 BCMA or TACI ( Figure 1A ; Table S1; Figure S1A ) using QuantiBRITE TM beads for antigen 1 2 quantification. We found expression of BCMA on CD138+ tumour cells from all patients 1 3 tested (median: 1061, range: 105-8323 ABC) ( Figure 1B ). TACI was co-expressed on 1 4 tumour ( Figure S1B ) and detected on MM cells from 39 of these patients, at generally lower 1 5 levels (median:333, range: 0-21301 ABC) ( Figure 1C ). Thus, we calculated that concurrent 1 6
targeting of both antigens compared to BCMA alone would increase levels of target antigen 1 7
in 78% of patients and result in an increased mean combined targetable antigen density on 1 8
tumour of 2458 ABC compared to 1623. TACI expression also exceeded BCMA in a subset 1 9
of samples (16%) ( Figure S1C ). Notably, 7 of these 8 patients expressed less than the 2 0 median level of BCMA suggesting that concurrent TACI targeting may be particularly 2 1 beneficial in a proportion of BCMA lo tumours.
2
In keeping with our previous findings 16 , patients with a new diagnosis of myeloma (54%) 2 3 expressed lower levels of BCMA (p<0.05) compared to relapsed disease (46%) but there 2 4
was no such correlation with TACI expression (p=0.3, Figure S1D ). Of the 42 (84%) of 2 5 patients for whom FISH was available, the 25 (60%) of patients with high risk cytogenetic 2 6
lesions had higher levels of BCMA (p<0.05 by Mann-Whitney) but a trend to lower levels of 2 7 TACI (p=0.06) ( Figure S1E ).
8
Thus we confirm the surface tumour expression of BCMA on tumour from all patients tested 2 9
and the co-expression of BCMA and TACI in the majority (78%) of patients, supporting a 3 0
therapeutic strategy for myeloma that targets both these antigens. 3 1 3 2
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Similar expression pattern of BCMA and TACI in normal tissues 1
The selectivity of BCMA expression to lymphoid cells 17 and more specifically PC has been 2 previously described 16 . TACI is also a known lymphoid antigen expressed mainly on B-cells, 3
but at an earlier stage of maturation and particularly in maturing subsets of splenic B-cells 38 . 4
As expression of TACI on normal tissues is less well known, we performed reverse 5 transcription-polymerase chain reaction (qRT-PCR) of BCMA and TACI in a range of normal 6 tissues. 7
Transcript analysis from 72 normal tissues, each from 3 donors, revealed highest levels of 8
BCMA and TACI expression in lymphoid tissues. Notable expression levels were also seen 9
in gastrointestinal and in bronchial tissues which likely reflects the presence of lymphocytes 1 0 at these anatomical sites. BCMA but not TACI expression was also noted in testes and gall 1 1 bladder ( Figure S2 ; Table S2 ). BCMA and TACI transcripts were equally high in the splenic 1 2 parenchyma but it is noteworthy that in other tissues BCMA gene expression was up to 10-1 3
fold higher than TACI. 1 4
These data are consistent with TACI expression being restricted to the lymphoid 1 5 compartment, with distribution broadly similar to that of BCMA. 1 6
Optimization of APRIL based CAR constructs 1 7
APRIL is a soluble ligand that binds BCMA and TACI. Additionally, the amino-terminus of 1 8
APRIL binds proteoglycans 39,40 but is not involved in the interaction with BCMA or TACI. To 1 9
confirm that a truncated form of APRIL could bind BCMA and TACI when expressed on a 2 0 cell surface, truncated APRIL was fused to the CD8 transmembrane domain and expressed 2 1 on SUPT1 cells. Staining with recombinant soluble BCMA and TACI confirmed that 2 2 truncated APRIL is both stably expressed and maintains BCMA and TACI binding when 2 3 membrane bound ( Figure S3A ). Further, surface plasmon resonance analysis of soluble 2 4
truncated APRIL binding to TACI and BCMA confirmed previously described binding kinetics 2 5
( Figure S3B ) 41 .
6
Next, three APRIL-based chimeric antigen receptors (ACAR) were constructed, consisting of 2 7
truncated APRIL fused to a spacer domain, a CD28 transmembrane and tripartite 2 8 endodomain (CD28-OX40-CD3ζ) 42 . Spacers were either the hinge of human IgG1 (ACAR-2 9 H), the stalk of human CD8α (ACAR-CD8) or the hinge, CH2 and CH3 domains of human 3 0
IgG1 modified to reduce Fc receptor binding 43 (ACAR-Fc) ( Figure 2A ). 3 1
PBMCs from normal donors were activated with IL-2, anti-CD28 and CD3 antibodies, 3 2
retrovirally transduced with ACAR constructs, CD56 depleted, and tested against SUPT1 3 3 cells modified to express high levels of either BCMA, TACI or non-transduced (NT) targets. 3 4
For personal use only. on January 9, 2018. by guest www.bloodjournal.org From Using 4 hour 51 Cr release assay, T-cells transduced with ACAR-H(n=5) and ACAR-1 CD8(n=6) spacer variants caused cytolysis of SUPT1 BCMA (p<0.01 for both ACAR constructs 2 compared to PBMC NT at an E:T ratio 16:1, paired t test) and SUPT1 TACI (p<0.05 for both 3 ACAR constructs) targets. In comparison, ACAR-Fc transduced T-cells killed SUPT1 BCMA 4 targets (n=3, p<0.05) but not TACI expressing targets ( Figure 2B ). 5
After co-culture with antigen expressing target cells (1:1 with irradiated, SUPT1 cells) for 24 6 hours, interferon gamma (IFNG) release from ACAR-H(n=5) and ACAR-CD8(n=6) T-cells 7 was detected. There was significant cytokine release observed on co-culture of both these 8 ACAR constructs with SUPT1 BCMA (p<0.01 for both) and SUPT1 TACI (p<0.05 for both) 9
compared to control targets. In comparison, ACAR-Fc did not result in cytokine release 1 0
against TACI or BCMA expressing SUPT1 cells (n=3) ( Figure 2C ). 1 1
To assess proliferation of ACAR T-cells, effector T-cells were stained with Cell Trace Violet 1 2 prior to 1:1 co-culture with SUPT1 targets and analysed by FACS at 4 days. Compared to 1 3 control co-cultures with SUPT1 NT targets, there was a significant increase in the percentage 1 4
of proliferated ACAR-H and ACAR-CD8 transduced T-cells with SUPT1 BCMA and SUPT1 TACI 1 5
(p<0.001 for both effectors with BCMA and TACI expressing targets) ( Figure 2D , Figure S4 ). 1 6
Taken together, these data indicate that both ACAR-CD8 and ACAR-H demonstrated 1 7
greater in vitro activity, compared with ACAR-Fc transduced T-cells. Both spacer variants 1 8
resulted in target cytolysis, cytokine release and effector proliferation in response to 1 9 SUPT1 BCMA or SUPT1 TACI . 2 0 APRIL CAR causes target cytolysis at low antigen densities, at a low E:T ratio, and in 2 1 the presence of soluble APRIL , BCMA and TACI 2 2
Clinical responses will likely require ACAR activity against the low levels of BCMA and TACI 2 3
found on some primary MM cells, and at low E:T ratios. We thus explored the in vitro 2 4
cytolytic potential of the two most promising ACAR constructs (ACAR-H and ACAR-CD8) 2 5 under these conditions. 2 6 ACAR transduced PBMCs were tested against SUPT1 targets expressing a wide range of 2 7
surface BCMA (421 to 1.5x10^5 ABC) and TACI (1063 to 6.3x10^4 ABC) ( Figure 3A ). By 2 8 51 Cr release, T-cells transduced with either ACAR construct caused significant cytolysis of all 2 9
BCMA and TACI expressing targets compared to control at all E:T ratios tested (32:1 to 4:1, 3 0
16:1 shown in Figure S5A ). In an attempt to more closely replicate physiological conditions, 3 1 co-cultures were then extended to 48 hours and the E:T ratio lowered to 1:10 and target kill 3 2 assessed by FACS. In these conditions, T-cells transduced with ACAR-H and ACAR-CD8 3 3 both caused significant target cytolysis of unirradiated targets expressing even the lowest 1 levels of BCMA and TACI ( Figure 3B ). 2 ACAR-mediated cytolysis of MM cells was confirmed in a number of human myeloma cell 3 lines (HMCLs, Figure S5B ). ACAR activity was also demonstrated at lower E:T ratios 4 against MM.1s and U266 HMCL with significant target cytolysis down to an E:T ratio of 1:32 5 on co-culture with T-cells transduced with both ACAR constructs ( Figure 3C) . T-cells 6
transduced with a BCMA-targeting CAR (BCMA CAR) based on the 11-D-5-3 17,24 scFv were 7 also compared to the ACAR and despite low E:T ratios, there was no statistically significant 8 difference in kill of MM.1s or U266 by the BCMA CAR and ACAR ( Figure S5C ). 9
Members of the TNF receptor superfamily found in the sera of MM patients may interfere 1 0
with an APRIL based therapeutic strategy by blockade or inadvertent T-cell activation. We 1 1 therefore quantified APRIL, BCMA and TACI in MM BM ( Figure S6A ), repeated cytotoxicity 1 2 assays with ACAR-H against MM.1s at low E:T ratios ( Figure S6B ) and measured IFNG 1 3 release ( Figure S6C ) in the presence of physiological levels of these proteins. There was no 1 4 significant cytokine release and ACAR-mediated target cytolysis was unaffected by sAPRIL 1 5
and sTACI but was reduced at the highest levels of sBCMA tested (p<0.001 at 1000ng/ml 1 6 compared to media control). 1 7
Therefore in vitro, T-cells transduced with both ACAR-H and ACAR-CD8 demonstrate 1 8 equivalent cytolytic activity and we consistently observed significant cytolysis of the lowest 1 9
BCMA and TACI expressers even at low E:T ratios. Furthermore, ACAR killing was 2 0 equivalent to that demonstrated by a scFv BCMA targeting CAR when used against BCMA 2 1 expressing targets. We also observed that ACAR T-cells are not activated by soluble ligand 2 2 and while tumour kill was also unaffected by physiological levels of soluble APRIL or TACI, 2 3 attenuation of target kill was seen at the highest levels of sBCMA. 2 4
APRIL CAR causes cytolysis of primary myeloma cells 2 5
To test ACAR activity on primary tumour cells, allogeneic PBMCs transduced with ACAR-H 2 6
and ACAR-CD8 variants were CD56 depleted, then co-cultured 1:1 with CD138-selected BM 2 7 derived MM cells from 5 patients. Although BCMA and TACI expression varied between 2 8 patient samples (BCMA 1224-7728 and TACI 563-1213 ABC, Figure 4A ), tumour cytolysis 2 9
and IFNG release were seen with both ACAR constructs in all samples. Survival and 3 0
proliferation of ACAR T-cells was seen with 3 patient samples (#23, #17, #1 in Figure 4A ). 3 1
Combining the results from the 5 patient samples, at D+3, ACAR-H and ACAR-CD8 resulted 3 2 in 72.9±12.2% and 87.7±5.4% tumour death respectively (mean± SEM cytolysis relative to 3 3 control). In comparison, baseline tumour cell death was 2.8±15.3% (p<0.05 for both ACAR 3 4
For personal use only. on January 9, 2018. by guest www.bloodjournal.org From constructs by paired t test). There was no significant difference in target kill, cytokine release 1
or T-cell expansion between the two ACAR spacer variants ( Figure 4B ). 2
We tested the ability of ACAR constructs to induce cytolysis by TACI alone by conducting 3 cytotoxicity assays in the presence of high concentrations of anti-BCMA monoclonal 4 antibody (S307118G03). We observed that the antibody blocked ACAR-mediated cytolysis 5 of U266 (BCMA+TACI-) but not MM.1s cells (BCMA+TACI+). Encouragingly, anti-BCMA 6 antibody did not attenuate killing of primary MM cells from 3 patients that expressed both 7
BCMA and TACI ( Figure 4C ). 8
Taken together, these experiments confirm ACAR-mediated cell death of primary MM cells 9
and support the assumption that, in the event of BCMA down-regulation, tumour control 1 0 could be maintained by TACI expression on primary cells. 1 1
Efficacy of APRIL CAR against myeloma in vivo 1 2
As these in vitro assays did not show a significant difference in efficacy of ACAR-H and 1 3
ACAR-CD8, we proceeded to test the smaller and thus simpler of the two constructs, ACAR-1 4
H in an in vivo model. 1 5
To establish an intramedullary myeloma model, 22 NSG mice were injected intravenously 1 6
with 10x10^6 HA+Fluc+MM.1s cells. Thirteen days later, there was intramedullary disease 1 7
by BLI in all mice ( Figure 5A ) at which point 5x10^6 EGFRvIII CAR or ACAR-H T-cells 1 8
( Figure 5B ) were administered by tail vein injection into 8 animals. A single animal in the 1 9
EGFRvIII CAR group did not recover following T-cells and a further mouse (with the lowest 2 0 disease burden pre-CAR) had disease clearance. Nonetheless, by 2 days, there was less 2 1 disease in ACAR than EGFRvIII CAR treated animals by BLI (p<0.01 by t test) and 2 2 continued disease suppression in ACAR treated mice ( Figure 5A-B) . At termination of the 2 3 experiment (D+12 post ACAR T-cells, D+25 post tumour cells) FACS of the BM confirmed 2 4 significant tumour clearance in ACAR treated animals compared to both control cohorts 2 5
(p<0.05 and p<0.001 compared to EGFRvIII CAR and untreated cohorts, Figure 5C ).
6
Tumour clearance in ACAR-H treated cohort was confirmed by immunohistochemistry 2 7
( Figure 5D ).
8
Human APRIL binds murine BCMA and TACI at similar affinities to their human isoforms 44 2 9
and ACAR causes equivalent cytolysis of SUPT1 targets expressing human or murine 3 0
BCMA and TACI ( Figure S7A ). This provided the unique opportunity to investigate possible 3 1 off target toxicity in our mouse xenograft model without modification to the ACAR construct. 3 2
Numerous tissues were harvested from test mice (full list in Supplementary data) and on 3 3 examination of formalin fixed and paraffin embedded (FFPE), haematoxylin and eosin (H&E) 3 4
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Persistent disease control in an in vivo escape model 3
We propose dual antigen targeting as a means of reducing the risk of antigen-negative 4
disease escape. To model the capacity for ACAR-mediated tumour control despite BCMA 5 downregulation, NSG mice were engrafted with a mix of SUPT1 BCMA and SUPT1 TACI (4:1 6 ratio) tumour cells by tail vein before administration of ACAR or BCMA CAR. 7
Twenty-one NSG mice were injected with 3.5x10^6 Fluc expressing SUPT1 cells comprising 8 SUPT1 BCMA (5807 ABC) and SUPT1 TACI (2229 ABC) (80%:20%). At 4 days mice received 9
5x10^6 NT T-cells, ACAR or BCMA CAR T-cells (n=7 per group) by tail vein injection. By 1 0
BLI, there was continued tumour growth with NT T-cells, partial disease suppression with 1 1
BCMA CAR and greatest tumour clearance in ACAR treated animals ( Figure 6A-B ). On 1 2
termination of the experiment (D+13 and D+9 post tumour and CAR respectively), FACS of 1 3
BM from animals receiving ACAR T-cells showed clearance of both SUPT1 BCMA and 1 4 SUPT1 TACI (p<0.001 and p<0.01 compared to NT respectively), while BM from animals 1 5
receiving BCMA CAR showed persistence of SUPT1 TACI (p=ns compared to NT). There was 1 6
continued engraftment of both tumour populations in animals receiving NT T-cells ( Figure  1  7 6C-D) and evident T-cell persistence in all mice ( Figure S8 ). 1 8
These data support the assumption that in comparison to targeting BCMA alone, dual 1 9
antigen targeting of BCMA and TACI facilitates continued disease suppression in the event 2 0
of BCMA downregulation or loss in patients who have tumour co-expression of both 2 1 antigens. 2 2 2 3 Discussion 2 4
BCMA is emerging as a lead therapeutic target in MM, as indicated by several on-going 2 5
clinical studies. The NCI group have reported 12 patients treated with their BCMA targeting 2 6
CD28-CD3ζ CAR 45 observing sustained responses at the highest dose level of 9x10^6 T-2 7 cells/kg 24 and a further 21 patients treated with a separate (bb2121) 4-1BB-CD3ζ CAR with 2 8 consistent responses in patients administered at least 150x10^6 CAR T-cells 46 . Cohen et al 2 9
have described their preliminary results of the first cohort treated with a 4-1BB-CD3ζ BCMA 3 0
CAR 47 . In this study, 3/9 patients developed grade 3-4 cytokine release syndrome but 3 1
notably, there were deep responses and evidence of CAR T-cell expansion without prior 3 2 lympho-depleting chemotherapy. Alternative T-cell redirecting therapies are CD3-BCMA 3 3 bispecific molecules on a common IgG arm 48,49 , or bi-specific T-cell engagers (BiTEs), where 1 scFvs to CD3 and BCMA are joined by a small peptide linker 23,50 . Additionally, a phase I 2 study of an antibody-drug conjugate utilising the anti-tubulin agent, monomethyl auristatin F, 3
reported an overall response rate of 67% in their high dose groups in multiply relapsed 4 patients 51 . 5
While these BCMA targeted therapies show promise, this receptor is present on tumour cells 6 at variable and often low levels 16, 17 . We found the median surface BCMA expression on MM 7 cells to be over a log less than CD19 on acute lymphoblastic leukemia (ALL) 6 . Moreover, 8
antigen negative tumour escape is well described in B-cell malignancies, with an incidence 9 exceeding 10% in patients with ALL treated with a CD19 CAR 6,25 . In the BCMA CAR study 1 0 described by the UPenn group 47 , disease progression in two patients was associated with 1 1 reduction in BCMA expression, reminiscent of the report from the NCI group using their first 1 2
BCMA CAR 24 . These observations prompt a re-evaluation of such therapies targeting a 1 3 single antigen. 1 4
We found BCMA and TACI to be co-expressed on tumour from the majority (78%) of 1 5
patients and we hypothesized that targeting two tumour antigens could overcome the 1 6
challenges of low target levels and antigen escape when targeting BCMA alone. To date, 1 7
there have been several approaches to creating dual targeting CARs. These strategies have 1 8
included the admixing of two populations of CAR transduced T-cells 52 , engineering a single 1 9
CAR construct containing two separate scFvs in tandem (TanCAR) 53, 54 or the co-expression 2 0 of 2 CARs on T-cells using a bi-cistronic vector or double transduction (OR gate) 55,56 . In the 2 1
context of low levels of target antigen, the first approach may not ensure maximal T-cell 2 2 activation as only BCMA or TACI would be recognised by individual T-cells. A bi-valent 2 3
TanCAR may result in lower numbers of ligated receptors per target cell in target limited 2 4
conditions; finally, an OR gate requires a large, complex bi-cistronic vector or a complex 2 5 double transduction.
6
In comparison, APRIL is compact (135aa), non-immunogenic and natively bispecific, binding 2 7
either MM antigen 31 with high affinity. Using APRIL as the CAR binder, we report target 2 8
cytolysis at low E:T ratios that enforce an assessment of serial kill and at low levels of target 2 9
antigen such as are present on primary tumour cells. ACAR-mediated cytolysis was also 3 0
achieved at low levels of TACI, when BCMA targeting was blocked thus indicating the 3 1 possibility of ACAR-mediated disease control even with BCMA down-regulation or loss. Data 3 2
exists demonstrating resistance of CARs to blocking by avidity effects 57,58 and we observed 3 3 reduction in ACAR killing at the highest levels of sBCMA found in MM BM but not with 3 4 physiological concentrations of APRIL or TACI. In confirmation of our in vitro findings, we 3 5 observed tumour regression of established disease after only 48 hours of ACAR T-cell 1 infusion in an intramedullary murine myeloma model. Notably, using an in vivo model of 2 tumour escape, we observed improved disease control compared to a CAR targeting BCMA 3 alone. 4 BCMA and TACI are both lymphoid antigens. BCMA is vital for the survival of long-lived 5 PC 59 , is upregulated in late memory B-cells on committing to the PC lineage 60,61 and is thus 6 present on normal and malignant PC 16, 17 . In comparison, TACI expression is found primarily 7 on maturing B-cells, particularly marginal zone B-cells, CD27+ memory B-cell subsets and 8
PC 38, 60 . Our qRT-PCR analysis of TACI transcripts indicates expression restricted to the 9 lymphoid compartments. Furthermore, ACAR does not appear to result in tissue toxicity in 1 0
an animal model. We expect that ACAR therapy would result in loss of the entire plasma cell 1 1 compartment and a subset of the B-cell compartment. The subsequent 1 2 hypogammaglobinaemia may be more profound than that of CD19 targeting 62 but should not 1 3 be more severe than that of BCMA targeting alone. 1 4
TACI has been implicated both as a positive and a negative immune regulator 63-66 , and gene 1 5
disruptions are found in 8% of patients with common variable immunodeficiency 27,64 . TACI 1 6
also drives PC differentiation 67 suggesting that TACI is expressed early in PC development. 1 7
We describe tumour TACI expression in the majority of patients and given the ontogeny of 1 8
TACI expression, speculate that in these patients at least, expression of this antigen on 1 9
putative myeloma stem cells which have a role in disease relapse and drug resistance 68,69 2 0
would add a further advantage to this approach. 2 1
In summary, using a novel ligand-based approach, we have demonstrated that the ACAR 2 2
can concurrently target BCMA and TACI to increase the number of targetable tumour 2 3
antigens in the majority of MM patients. ACAR T-cells were able to kill targets expressing 2 4 either receptor and significant killing was seen at physiological receptor levels, at low E:T 2 5 ratios or with BCMA blockade. ACAR T-cells also killed primary myeloma cells in vitro and 2 6
we observed rapid and complete tumour clearance in vivo in comparison to an irrelevant 2 7
CAR as well as in our tumour escape model compared to a CAR targeting BCMA alone. 2 8
These observations suggest that dual antigen targeting of BCMA and TACI by ACAR T-cells 2 9
may improve on the initial clinical responses seen with BCMA targeting CARs, both by 3 0
extending clinical applicability to those patients with low levels of tumour BCMA, and by 3 1
reducing the risk of antigen negative escape. based 3 rd generation chimeric antigen receptors (ACAR) were constructed, consisting of a 3 5 truncated APRIL molecule, fused to a tripartite endodomain (CD28-OX40-CD3ζ) via one of determined relative to viable tumour cells on co-culture with NT T-cells) (ii)cytokine release staining respectively with numbers normalised to Flow-Check TM beads to calculate relative 1 engraftment. Mean±SEM shown, **=p<0.01 and ***=p<0.001 by t test. 2 3 4
